Thursday , August 11 2022
Home / Business / ‘Groundbreaking approach’: Imugene deal looks to smash solid tumours

‘Groundbreaking approach’: Imugene deal looks to smash solid tumours

Imugene, the cancer treatment maker chaired by biotech veteran Paul Hopper, is banking on a partnership with Nasdaq-listed biotech Celularity to unlock a revolutionary treatment that will ‘obliterate’ solid tumours.

The Sydney-based company, which has seen its share price almost triple this year, on Thursday unveiled a research partnership that will combine its immunotherapy candidate OnCARlytics with Celularity’s cell therapy CyCART-19.

The aim is to create a new and targeted approach to destroying tumours that have traditionally been tough to fight.

“We just are really curious about the science, we really want to get there,” said Imugene CEO Leslie Chong.

“We just are really curious about the science, we really want to get there,” said Imugene CEO Leslie Chong.Credit:Paul Jeffers

Imugene’s treatment uses a specific cancer-fighting virus to target tumours, entering cells and prompting them to start producing the antigen CD19. Solid tumours don’t typically produce CD19 molecules, but nudging them to do so will prime them to then be hit by Celularity’s placenta-derived stem cell treatment.

“The idea here is for [our] oncolytic therapy to prime the solid tumours – and express the CD19, which shrouds it and covers it so in combination with CyCART19, we can obliterate the solid tumour,” chief executive Leslie Chong said.

Robert Hariri, the founder of Celularity, said the two companies’ research projects aligned perfectly.

“The combination of the two is invaluable – it can literally set the stage for how to go after and treat a range of solid malignancies,” he said.

The companies have not yet worked out how future research costs will be shared, with the initial collaboration set to involve work that has already been budgeted for. Timelines for human trials of the treatments are also not set yet, but the businesses hope to be enrolling patients within the next year.

Dr Hariri said early data from the research was likely to interest investors globally.

About admin

Check Also

Playing the long game with career goals after graduation

“However, generalist degrees (arts, science, etc) do catch up in the medium term as this …